Vericel Corp (NASDAQ:VCEL) was the target of a large growth in short interest in December. As of December 29th, there was short interest totalling 1,430,058 shares, a growth of 37.6% from the December 15th total of 1,039,625 shares. Based on an average daily trading volume, of 451,988 shares, the days-to-cover ratio is presently 3.2 days. Approximately 4.1% of the shares of the stock are sold short.
A number of research firms have weighed in on VCEL. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $9.00 target price on shares of Vericel in a report on Tuesday, January 2nd. ValuEngine lowered Vericel from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, BTIG Research set a $6.00 target price on Vericel and gave the company a “buy” rating in a report on Monday, October 2nd.
Vericel (NASDAQ:VCEL) opened at $6.63 on Friday. The company has a current ratio of 2.50, a quick ratio of 2.22 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $225.15, a PE ratio of -7.53 and a beta of 3.02. Vericel has a twelve month low of $2.25 and a twelve month high of $6.75.
Vericel (NASDAQ:VCEL) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.01. The business had revenue of $14.26 million during the quarter. Vericel had a negative return on equity of 265.45% and a negative net margin of 45.11%. equities research analysts expect that Vericel will post -0.6 earnings per share for the current fiscal year.
A number of hedge funds have recently bought and sold shares of VCEL. Bank of New York Mellon Corp grew its holdings in shares of Vericel by 13.8% during the second quarter. Bank of New York Mellon Corp now owns 37,202 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 4,523 shares in the last quarter. Citadel Advisors LLC purchased a new position in shares of Vericel during the third quarter worth about $235,000. JPMorgan Chase & Co. purchased a new position in shares of Vericel during the third quarter worth about $328,000. EAM Investors LLC purchased a new position in shares of Vericel during the third quarter worth about $943,000. Finally, Perkins Capital Management Inc. grew its holdings in shares of Vericel by 118.4% during the third quarter. Perkins Capital Management Inc. now owns 562,600 shares of the biotechnology company’s stock worth $3,376,000 after purchasing an additional 305,000 shares in the last quarter. 33.12% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This report was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.thelincolnianonline.com/2018/01/14/vericel-corp-vcel-short-interest-up-37-6-in-december.html.
Vericel Company Profile
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.